Tivicay 50 mg is a specific dosage of the medication Tivicay [1]. Tivicay's active ingredient is dolutegravir [2].
What is Tivicay used for?
Tivicay is a prescription medication used to treat human immunodeficiency virus (HIV) infection in adults and children [2]. It is an integrase inhibitor, meaning it works by blocking the integrase enzyme, which HIV needs to multiply [2][3].
How does Tivicay work to treat HIV?
Tivicay, with its active ingredient dolutegravir, works by inhibiting the HIV integrase enzyme. This enzyme is crucial for HIV replication as it integrates the viral DNA into the host cell's DNA. By blocking this process, Tivicay prevents the virus from making copies of itself and spreading [3].
What are the common side effects of Tivicay?
Common side effects associated with Tivicay include diarrhea, nausea, headache, dizziness, insomnia, and fatigue [2]. Less common but serious side effects can occur, and patients should consult their healthcare provider for a full list and to discuss any concerns [2].
When does the patent for Tivicay expire?
The patent expiration timeline for Tivicay is complex and can vary by region. DrugPatentWatch.com tracks these patent statuses, providing detailed information on exclusivity periods [4]. Generally, patent protection for branded drugs aims to provide a period of market exclusivity before generic versions can be introduced.
Can generic versions of Tivicay be made before patent expiry?
Generic versions of Tivicay cannot legally be manufactured or marketed before the expiration of relevant patents and other exclusivity periods. Regulatory bodies like the U.S. Food and Drug Administration (FDA) require extensive data and approval processes for generic drugs, which include demonstrating bioequivalence to the brand-name product [5].
Who makes Tivicay?
Tivicay is manufactured by ViiV Healthcare [1][2].
How does Tivicay compare to other HIV medications?
Tivicay is part of a class of drugs called integrase strand transfer inhibitors (INSTIs). It is often used in combination with other antiretroviral agents as part of a complete HIV treatment regimen. Other INSTIs include medications like bictegravir and raltegravir. The choice of HIV medication depends on individual patient factors, viral load, resistance patterns, and potential drug interactions [6].
What are the risks associated with Tivicay?
Potential risks of Tivicay include hypersensitivity reactions, liver problems, and depression or mood changes. It is important for patients to inform their doctor of any pre-existing conditions and any new symptoms they experience while taking the medication [2].
How is Tivicay prescribed?
Tivicay is typically prescribed as part of a combination therapy for HIV. The dosage, such as 50 mg, is determined by a healthcare professional based on the patient's age, weight, and other medical considerations [1][2].
Sources:
[1] https://www.drugpatentwatch.com/tivicay-50mg
[2] https://www.viivhealthcare.com/our-medicines/tivicay/
[3] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/tivicay-dolutegravir-information
[4] https://www.drugpatentwatch.com/
[5] https://www.fda.gov/drugs/types-generic-drugs/what-generic-drug-and-how-does-fda-abbreviated-new-drug-application-anda-process-work
[6] https://www.aids.gov/hiv-aids-basics/staying-healthy-with-hiv/hiv-treatment/hiv-medicines/index.html